Cited 0 times in
Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.